Sonoma Pharmaceuticals
SNOA
14 hedge funds and large institutions have $136K invested in Sonoma Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
1.58% less ownership
Funds ownership: 3.9% → 2.31% (-1.6%)
5% less capital invested
Capital invested by funds: $144K → $136K (-$7.44K)
18% less funds holding
Funds holding: 17 → 14 (-3)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$57.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$11.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.77K |
| 4 |
Barclays
London,
United Kingdom
|
+$655 |
| 5 |
HI
Harbour Investments
Madison,
Wisconsin
|
+$21 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$25.6K |
| 2 |
Citigroup
New York
|
-$3.04K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.62K |
| 4 |
JP Morgan Chase
New York
|
-$255 |
| 5 |
US Bancorp
Minneapolis,
Minnesota
|
-$53 |
SNOA Hedge Fund Activity: Q2 2026 in Review
14 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2026, worth a combined $136K — down 5.2% from $144K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SNOA and 4 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $57.8K. The largest seller was DRW Securities, exiting entirely with an estimated $25.6K sold.
- 14 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2026, down from 17 in Q1 2026.
- Funds reported $136K of Sonoma Pharmaceuticals stock for Q2 2026, down 5.2% quarter-over-quarter.
- 4 funds opened new Sonoma Pharmaceuticals positions in Q2 2026 and 6 closed out, a net change of -2 holders.
- The largest Sonoma Pharmaceuticals buyer in Q2 2026 was Renaissance Technologies, an estimated $57.8K added.
- The largest Sonoma Pharmaceuticals seller in Q2 2026 was DRW Securities, an estimated $25.6K sold.
Based on aggregated 13F filings for Q2 2026.